All SARS-CoV-2 articles – Page 3
-
NewsSilver nanoparticles produced by fungus could be used to prevent and treat COVID-19
Silver nanoparticles produced by the fungus Trichoderma reesei could become important allies in the prevention and treatment of COVID-19. Tests on hamsters showed that they not only inhibited the infection but also reduced the viral load in the lungs.
-
NewsLong COVID may cause long-term changes in the heart and lungs and may lead to cardiac and pulmonary diseases
Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS-CoV-2 infection, potentially placing them at elevated risk for future cardiac and pulmonary conditions.
-
NewsClinical trial underway for potential Long COVID treatment
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca’s long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid.
-
NewsLong COVID biomarkers found – associated with respiratory problems
Researchers have identified biomarkers in the blood associated with symptoms of long COVID, particularly severe respiratory disorders. The discovery can pave the way for future diagnosis and treatment.
-
NewsCOVID-19 vaccinations are metabolically safe, research finds
New research confirms that multiple doses of COVID-19 vaccines do not cause significant metabolic changes, offering reassurance for those concerned about potential long-term side effects of vaccination.
-
NewsBNT162b2 vaccine not only targets COVID-19 virus, but may also help control innate inflammation
New findings suggest the BNT162b2 vaccine may reduce the production of pro-inflammatory mediators to bacterial, fungal or viral infections by reprogramming innate immune cells to regulate inflammation.
-
NewsStudy of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients
A study used five analytical methods to show that oral azvudine has a therapeutic effect in elderly COVID-19 patients aged over 60 years.
-
NewsCertain nasal bacteria may boost the risk for COVID-19 infection, study finds
Certain types of nasal bacteria can affect the levels of key proteins the Covid-19 virus needs to enter human cells, offering new insight into why some people are more vulnerable to the disease than others.
-
NewsInvesting in COVID-19 vaccination more than paid off for U.S., study finds
The US national Covid-19 vaccine strategy more than paid for itself after just one year, according to a new study. Because the vaccines reduced how many people developed serious illness or died, the nation saved more money than it spent.
-
NewsTackling the ‘silent pandemic’: breakthrough study puts first long COVID treatment on horizon
Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.
-
NewsAI learns to ‘speak’ genetic ‘dialect’ for future SARS-CoV-2 mutation prediction
Researchers have developed a new method to predict mutations in virus protein sequences called Deep Novel Mutation Search (DNMS), a type of artificial intelligence model that uses deep neural networks.
-
NewsmRNA-based COVID-19 vaccines train the ‘long-term memory’ of the innate immune system
A study showed that vaccination of multiple mRNA-based COVID-19 vaccines could induce persistent epigenetic changes in innate immune cells, leading to long-term immune responses for SARS-CoV-2 and other pathogens.
-
News‘It’s a shot, not a vaccine like MMR’: New skepticism prompts call for action
This ‘vaccine is not a vaccine’ is a new, previously unreported type of vaccine-specific scepticism, and it arose only during the COVID-19 pandemic. However, it might, according to the researchers, also apply to the flu vaccine.
-
News‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
A universal vaccine for coronaviruses removes sugar molecules from an area of a coronavirus spike protein that rarely mutates and creates effective and plentiful antibodies to inactivate the virus.
-
NewsUKHSA highlights pathogens of greatest risk to public health in bid to boost preparedness
The UK Health Security Agency (UKHSA) has today published its view on the pathogen families that could pose the greatest risk to public health, in a bid to focus and guide preparedness efforts against these threats.
-
NewsScientists ID natural products targeting SARS-CoV-2 - including caffeine
Researchers used computational methods to identify potential inhibitors of SARS-CoV-2 spike proteins, revealing promising natural compounds for guiding antiviral drug development, including caffeine.
-
NewsAntibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
-
NewsMcMaster leads Canada’s first-ever guidelines for Post COVID-19 Condition
A team of experts from McMaster University has led the creation of Canada’s first-ever comprehensive guidelines for diagnosing, managing, preventing, and treating post COVID-19 condition (PCC), more commonly known as long COVID.
-
NewsCOVID-19 pandemic worsened mother and infant birth outcomes
Mothers who became pregnant after the start of the pandemic, those who experienced moderate-to-severe infections during pregnancy, and those who had infections during the third trimester were more likely to have adverse outcomes.
-
NewsCeSPIACE: A broad-spectrum peptide inhibitor against variable SARS-CoV-2 spikes
CeSPIACE, a small remodified peptide, is able to block the binding of ACE2 receptor and the spike protein on SARS-CoV-2 and its variants. Hence, the cheap and simple peptide could treat COVID-19 infection and prevent reinfection after exposure of the virus.